TG Therapeutics | TGTX - Current Liabilities


TG Therapeutics reported $187.11M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Amgen USD 24.96B 534M Mar/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
Bayer EUR 33.46B 875M Mar/2026
Biogen USD 3B 350.5M Mar/2026
Corcept Therapeutics USD 149.18M 16.9M Mar/2026
Curis USD 14.08M 5.3M Dec/2025
Gilead Sciences USD 9.48B 2.34B Mar/2026
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 342.46M 117.49M Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
TG Therapeutics USD 187.11M 33.35M Mar/2026
Verastem USD 72.27M 12.56M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026